Centrum fuer innovative Diagnostik und Therapie Rheumatologie/Immunologie c i r i GmbH

At the Centrum fuer innovative Diagnostik und Therapie Rheumatologie/Immunologie c i r i GmbH in Frankfurt, researchers are focusing on immune‑mediated conditions, primarily exploring new biologic treatments for psoriatic arthritis.

• Long‑term safety assessment of novel biologics
• Comparative efficacy of targeted therapies
• Evaluation of treatment response in patients with prior DMARD failure

The work supports the development of safer, longer‑acting therapies for patients who have not responded adequately to standard disease‑modifying drugs.

The site’s program in skin and connective tissue diseases centers on improving outcomes for adults with active psoriatic arthritis through innovative drug evaluations.

• Investigation of subcutaneous administration regimens
• Placebo‑controlled efficacy trials
• Optimization of treatment pathways for skin‑related joint disease

These studies aim to expand therapeutic options for individuals with challenging disease courses, aligning with the company’s commitment to advancing rheumatology care.